BM88/Cend1 is involved in histone deacetylase inhibition-mediated growth arrest and differentiation of neuroblastoma cells

FEBS Letters

Volumn 582, Issue 5, 2008, Pages 741-748

  Politis, Panagiotis K ^a   Akrivou, Sofia ^a   Hurel, Catherine ^a   Papadodima, Olga ^a   Matsas, Rebecca ^a  

^a HELLENIC PASTEUR INSTITUTE   (Greece)

Author keywords

III Tubulin; Acetylation; Proliferation; Promoter activation; Transcription; Trichostatin A

Indexed keywords

CELL PROTEIN; HISTONE DEACETYLASE; PROTEIN CEND1; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CELL GROWTH; CONTROLLED STUDY; GENETIC TRANSCRIPTION; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; MEMBRANE PROTEINS; MICE; NERVE TISSUE PROTEINS; NEUROBLASTOMA; NEURONS; NIH 3T3 CELLS; PROMOTER REGIONS (GENETICS); PROTEIN BIOSYNTHESIS; REPRESSOR PROTEINS; RNA, MESSENGER; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 39649113332     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2008.01.052     Document Type: Article

References (21)

1. Minucci S., and Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6 (2006) 38-51
2. Yoshida M., Horinouchi S., and Beppu T. Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays 17 (1995) 423-430
3. He L.Z., Tolentino T., Grayson P., Zhong S., Warrell Jr. R.P., Rifkind R.A., Marks P.A., Richon V.M., and Pandolfi P.P. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin. Invest. 108 (2001) 1321-1330
4. Jaboin J., Wild J., Hamidi H., Khanna C., Kim C.J., Robey R., Bates S.E., and Thiele C.J. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res. 62 (2002) 6108-6115
5. Coffey D.C., Kutko M.C., Glick R.D., Butler L.M., Heller G., Rifkind R.A., Marks P.A., Richon V.M., and La Quaglia M.P. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res. 61 (2001) 3591-3594
6. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1 (2002) 287-299
7. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., and Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1 (2001) 194-202
8. Inokoshi J., Katagiri M., Arima S., Tanaka H., Hayashi M., Kim Y.B., Furumai R., Yoshida M., Horinouchi S., and Omura S. Neuronal differentiation of neuro 2a cells by inhibitors of cell cycle progression, trichostatin A and butyrolactone I. Biochem. Biophys. Res. Commun. 256 (1999) 372-376
9. Ajamian F., Salminen A., and Reeben M. Selective regulation of class I and class II histone deacetylases expression by inhibitors of histone deacetylases in cultured mouse neural cells. Neurosci. Lett. 365 (2004) 64-68
10. Curtin B.F., Tetz L.M., Compton J.R., Doctor B.P., Gordon R.K., and Nambiar M.P. Histone acetylase inhibitor trichostatin A induces acetylcholinesterase expression and protects against organophosphate exposure. J. Cell Biochem. 96 (2005) 839-849
11. Koutmani Y., Hurel C., Patsavoudi E., Hack M., Gotz M., Thomaidou D., and Matsas R. BM88 is an early marker of proliferating precursor cells that will differentiate into the neuronal lineage. Eur. J. Neurosci. 20 (2004) 2509-2523
12. Mamalaki A., Boutou E., Hurel C., Patsavoudi E., Tzartos S., and Matsas R. The BM88 antigen, a novel neuron-specific molecule, enhances the differentiation of mouse neuroblastoma cells. J. Biol. Chem. 270 (1995) 14201-14208
13. Georgopoulou N., Hurel C., Politis P.K., Gaitanou M., Matsas R., and Thomaidou D. BM88 is a dual function molecule inducing cell cycle exit and neuronal differentiation of neuroblastoma cells via cyclin D1 down-regulation and retinoblastoma protein hypophosphorylation. J. Biol. Chem. 281 (2006) 33606-33620
14. Politis P.K., Rohrer H., and Matsas R. Expression pattern of BM88 in the developing nervous system of the chick and mouse embryo. Gene Expr. Patterns 7 (2007) 165-177
15. Politis P.K., Makri G., Thomaidou D., Geissen M., Rohrer H., and Matsas R. BM88/CEND1 coordinates cell cycle exit and differentiation of neuronal precursors. Proc. Natl. Acad. Sci. USA 104 (2007) 17861-17866
16. Papadodima O., Sergaki M., Hurel C., Mamalaki A., and Matsas R. Characterization of the BM88 promoter and identification of an 88 bp fragment sufficient to drive neurone-specific expression. J. Neurochem. 95 (2005) 146-159
17. Sowa Y., Orita T., Minamikawa S., Nakano K., Mizuno T., Nomura H., and Sakai T. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem. Biophys. Res. Commun. 241 (1997) 142-150
18. Zhang Y., and Dufau M.L. Silencing of transcription of the human luteinizing hormone receptor gene by histone deacetylase-mSin3A complex. J. Biol. Chem. 277 (2002) 33431-33438
19. Lagger G., Doetzlhofer A., Schuettengruber B., Haidweger E., Simboeck E., Tischler J., Chiocca S., Suske G., Rotheneder H., Wintersberger E., and Seiser C. The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene. Mol. Cell Biol. 23 (2003) 2669-2679
20. Emili A., Greenblatt J., and Ingles C.J. Species-specific interaction of the glutamine-rich activation domains of Sp1 with the TATA box-binding protein. Mol. Cell Biol. 14 (1994) 1582-1593
21. Saluja D., Vassallo M.F., and Tanese N. Distinct subdomains of human TAFII130 are required for interactions with glutamine-rich transcriptional activators. Mol. Cell Biol. 18 (1998) 5734-5743